nefazodone has been researched along with Anxiety Neuroses in 17 studies
nefazodone: may be useful as an opiate adjunct
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nefazodone is a recently marketed compound with demonstrated efficacy in major depression." | 9.08 | An open-label trial of nefazodone in high comorbidity panic disorder. ( DeMartinis, NA; Rickels, K; Schweizer, E, 1996) |
| "681 patients with chronic major depressive disorder (DSM-IV criteria) participated in a multicenter study of 12 weeks of acute treatment with nefazodone (N = 226), CBASP (N = 228), or the combination (N = 227)." | 5.10 | Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. ( Borian, FE; Crits-Christoph, P; Keller, MB; Kornstein, SG; Manber, R; Ninan, PT; Rothbaum, BO; Rush, AJ; Thase, ME; Trivedi, MH; Zajecka, J, 2002) |
| "Nefazodone is a recently marketed compound with demonstrated efficacy in major depression." | 5.08 | An open-label trial of nefazodone in high comorbidity panic disorder. ( DeMartinis, NA; Rickels, K; Schweizer, E, 1996) |
| "Nefazodone treatment was associated with marked clinical improvement." | 2.72 | The neural correlates of social anxiety disorder and response to pharmacotherapy. ( Bowman, FD; Ely, TD; Gordon, A; Gross, RE; Kelsey, JE; Kilts, CD; Knight, B; Nemeroff, CB; Newport, DJ; Selvig, A, 2006) |
| "Nefazodone was efficacious in symptom alleviation in patients with comorbid anxiety and depression." | 2.71 | Mixed anxiety and depression in older adults: clinical characteristics and management. ( Cassidy, EL; Lauderdale, S; Sheikh, JI, 2005) |
| "Imipramine treatment was not significantly better than placebo for improvement in depression and anxiety ratings in this patient group." | 2.68 | The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings. ( Zajecka, JM, 1996) |
| "Nefazodone is a recently released antidepressant that potently antagonizes the serotonin type 2A receptor and blocks uptake of norepinephrine and serotonin." | 2.68 | An open trial of nefazodone in adult patients with generalized anxiety disorder. ( Halls, CH; Hedges, DW; Reimherr, FW; Rust, C; Strong, RE, 1996) |
| "Lifetime psychiatric illness is also common in women with PMDD, and although mood disorders predominate, past histories of anxiety disorders are also common, further suggesting an association between PMDD and anxiety disorders." | 2.40 | Anxiety symptoms and anxiety disorders: how are they related to premenstrual disorders? ( Yonkers, KA, 1997) |
| "Nefazodone-treated patients showed significantly greater improvement in somatic anxiety (HAM-D item 11) ratings than placebo-treated patients from Week 4 through end of treatment (p < or = ." | 2.39 | Response of anxiety and agitation symptoms during nefazodone treatment of major depression. ( Anton, SF; Fawcett, J; Marcus, RN; O'Brien, K; Schwiderski, U, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (47.06) | 18.2507 |
| 2000's | 9 (52.94) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Preskorn, SH | 1 |
| Manber, R | 3 |
| Kraemer, HC | 1 |
| Arnow, BA | 2 |
| Trivedi, MH | 2 |
| Rush, AJ | 4 |
| Thase, ME | 3 |
| Rothbaum, BO | 2 |
| Klein, DN | 2 |
| Kocsis, JH | 2 |
| Gelenberg, AJ | 1 |
| Keller, ME | 1 |
| Cassidy, EL | 1 |
| Lauderdale, S | 1 |
| Sheikh, JI | 1 |
| Kilts, CD | 1 |
| Kelsey, JE | 1 |
| Knight, B | 1 |
| Ely, TD | 1 |
| Bowman, FD | 1 |
| Gross, RE | 1 |
| Selvig, A | 1 |
| Gordon, A | 1 |
| Newport, DJ | 1 |
| Nemeroff, CB | 1 |
| Blasey, C | 1 |
| Constantino, MJ | 1 |
| Markowitz, JC | 1 |
| Fawcett, J | 1 |
| Marcus, RN | 1 |
| Anton, SF | 1 |
| O'Brien, K | 1 |
| Schwiderski, U | 1 |
| Zajecka, JM | 1 |
| Rothschild, AJ | 1 |
| DeMartinis, NA | 1 |
| Schweizer, E | 1 |
| Rickels, K | 1 |
| Hedges, DW | 1 |
| Reimherr, FW | 1 |
| Strong, RE | 1 |
| Halls, CH | 1 |
| Rust, C | 1 |
| Yonkers, KA | 1 |
| DeVane, CL | 1 |
| Grothe, DR | 2 |
| Smith, SL | 2 |
| Charney, DS | 1 |
| Brady, KT | 1 |
| Kaltsounis-Puckett, J | 1 |
| Wright, CW | 1 |
| Laird, LK | 1 |
| Hales, RE | 1 |
| Hilty, DM | 1 |
| Brunson, GH | 1 |
| Ninan, PT | 1 |
| Crits-Christoph, P | 1 |
| Kornstein, SG | 1 |
| Zajecka, J | 1 |
| Borian, FE | 1 |
| Keller, MB | 1 |
| Copp, JE | 1 |
| Schwiderski, UE | 1 |
| Robinson, DS | 1 |
6 reviews available for nefazodone and Anxiety Neuroses
| Article | Year |
|---|---|
Response of anxiety and agitation symptoms during nefazodone treatment of major depression.
Topics: Adult; Antidepressive Agents; Anxiety Disorders; Comorbidity; Depressive Disorder; Double-Blind Meth | 1995 |
The diagnosis and treatment of late-life depression.
Topics: Age Factors; Aged; Antidepressive Agents; Anxiety Disorders; Bupropion; Cyclohexanols; Depressive Di | 1996 |
Anxiety symptoms and anxiety disorders: how are they related to premenstrual disorders?
Topics: 1-Naphthylamine; Adult; Age of Onset; Anxiety; Anxiety Disorders; Buspirone; Carbon Dioxide; Comorbi | 1997 |
Pharmacology of antidepressants: focus on nefazodone.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Depressive Disorder; Drug Interactions; | 2002 |
Overview of psychiatric disorders and the role of newer antidepressants.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Depressive Disor | 2002 |
Cost savings with nefazodone in treating depression.
Topics: Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cost Savings; Depr | 2002 |
8 trials available for nefazodone and Anxiety Neuroses
| Article | Year |
|---|---|
Mixed anxiety and depression in older adults: clinical characteristics and management.
Topics: Aged; Aging; Antidepressive Agents, Second-Generation; Anxiety Disorders; Comorbidity; Depressive Di | 2005 |
The neural correlates of social anxiety disorder and response to pharmacotherapy.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Anxiety Disorders; Brain; Bra | 2006 |
Dropouts versus completers among chronically depressed outpatients.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Anxiety Disorder | 2007 |
The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings.
Topics: Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Anxiety Disorders; Community | 1996 |
An open-label trial of nefazodone in high comorbidity panic disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Comorbidity; Depression; Depress | 1996 |
An open trial of nefazodone in adult patients with generalized anxiety disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Female; Humans; Male; Middle Age | 1996 |
Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Chronic Disease; Cognitive Behav | 2002 |
Symptom comorbidity in anxiety and depressive disorders.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Buspirone; Depressive Disorder; Double-Blind Method; | 1990 |
3 other studies available for nefazodone and Anxiety Neuroses
| Article | Year |
|---|---|
How multiple medication use evolves and the importance of therapeutic trials: the slippery slide.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Asthma; Broncho | 2008 |
Faster remission of chronic depression with combined psychotherapy and medication than with each therapy alone.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Chronic Disease; Cognitive Behavi | 2008 |
New perspectives in the management of depression. Symposium highlights from ECNP, Venice, September 1995.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Comorbidity; Depressive Disorder; Human | 1996 |